ITGAM and metastatic neoplasm: PBMCs from dogs with advanced or metastatic cancer showed a marked increase in the CD11b+CD14−MHCII− fraction of cells, which accounted for the majority of the cells in the live cell gate, compared to dogs diagnosed with early stage non-metastatic tumors or healthy dog controls (Fig. 1A).